Colorectal Cancer

Cancer Screening: Theory and Practice

Volumn , Issue , 2021, Pages 219-265

  Cuzick, Jack ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85130948938     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780429179587-13     Document Type: Chapter

References (179)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of a eighteen major cancers in 1985. Int J Cancer 1993; 54:594-606.
2. Pisani P, Parkin DM, Ferlay J. Estimates of the world-wide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55:891-903.
3. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 1954; 8:1-12.
4. Doll R. The age distribution of cancer: implications for models of carcinogenesis. Royal Statistical Society A 1971; 134:133-166.
5. Vukasin AP, Ballantyne GH, Flannery JT, et al. Increasing incidence of cecal and sigmoid carcinoma: data from the Connecticut Tumor Registry. Cancer 1990; 66:2442-2449.
6. Levi F, Randimbison L, La Vecchia C. Trends in subsite distribution of colorectal cancers and polyps from the Vaud Cancer Registry. Cancer 1993; 72:46-50.
7. Slattery ML, Friedman GD, Potter JD, et al. A description of age, sex and site distributions of colon not rectum carcinoma in three geographic areas. Cancer 1996; 78:1666-1670.
8. Stower MJ, Hardcastle JD. The results of 1115 patients with colorectal cancer treated over an 8-year period in a single hospital. Eur J Surg Oncol 1985; 11:119-123.
9. Miller BA, Ries LAG, Hankey BF, et al eds. SEER Cancer Statistics Review: 1973-1990 [NIH Pub. No. 93-2789]. National Cancer Institute. 1993.
10. Chu KC, Tarone RE, Chow W-H, Hankey BF, Ries LA. Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990. J Natl Cancer Inst 1994; 86:997-1006.
11. International Agency for Research on Cancer. Trends in Cancer Incidence and Mortality. [IARC Scientific Publications No. 121]. Lyon: International Agency for Research on Cancer, 1993.
12. Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968; 40:43-68.
13. Steinitz R, Parkin DM, Young JL, Bieber CA, Katz L. Cancer Incidence in Jewish Migrants to Israel 1961-1981 [IARC Scienific Publications No. 98]. Lyon: International Agency for Research on Cancer, 1989.
14. McMichael AJ. Alimentary tract cancer in Australia in relation to diet and alcohol. Nutr Cancer 1979; 1:82-89.
15. Whittemore AS. Colorectal cancer incidence among Chinese in North America and the People’s Republic of China: variation with sex, age and anatomical site. Int J Epidemiol 1989; 18:563-568.
16. Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer: a review of the epidemiology. Epidemiol Rev 1993; 15:499-545.
17. Trock B, Lanza E, Greenwald P. Dietary fiber, vegetables, and colon cancer: critical review and meta-analyses of the epidemiologic evidence. J Natl Cancer Inst 1990; 82:650-661.
18. Block G, Patterson B, Subar A. Fruit, vegetables and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 1992; 18:1-29.
19. Mehta RG, Liu J, Constantinou A, Thomas CF, Hawthorne M, You M, Gerhauser C, Pezzuto JM, Moon RC, Moriarty RM. Cancer chemopreventive activity of brassinin, a phytoalexin from cabbage. Carcinogenesis 1995; 16:399-404.
20. Greenberg ER, Baron JA, Tosteson TD, et al. A clinical trial of antioxidant vitamins to prevent colorectal cancer. N Engl J Med 1994; 331:141-147.
21. MacLennan R, Macrae F, Bain C, Battistutta D, Chapuis P, Gratten H, Lambert J, Newland RC, Ngu M, Russell A, Ward M, Wahlqvist ML. Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. J Natl Cancer Inst 1995; 87:1760-1766.
22. ATBC Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330:1029-1035.
23. Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards BK, Rautalahti M, Hartman AM, Palmgren J, Freedman LS, Haapakoski J, Barrett MJ, Pietinen P, Malila N, Tala E, Liippo K, Salomaa E-R, Tangrea JA, Teppo L, Askin FB, Taskinen E, Erozan Y, Greenwald P, Huttunen JK. cc-Tocopherol and p-carotene supplements and lung cancer incidence in the Alpha-tocopherol, Beta-Carotene Cancer Prevention Study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996; 88:1560-1570.
24. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Cherniack MG, Brodkin CA, Hammar S. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996, 88:1550-1559.
25. La Vecchia C, Ferraroni M, Mezzetti M, et al. Attributable risks for colorectal cancer in northern Italy. Int J Cancer 1996; 66:60-64.
26. Burkitt DP. Epidemiology of cancer of the colon and rectum. Cancer 1971; 28:3-13.
27. Howe GR, Benito E, Castellato R, et al. Dietary intake of fiber and decreased risk of cancers of the colon and rectum: evidence from the combined analysis of 13 case-control studies. J Natl Cancer Inst 1992; 84:1887-1896.
28. Macquart-Moulin G, Riboli E, Cornee J, et al. Case-control study on colorectal cancer and diet in Marseilles. Int J Cancer 1986; 38:183-191.
29. La Vecchia C, Negri E, Decarli A, D’Avanzo B, Gallotti L, Gentile A, Franceschi S. A case-control study of diet and colorectal cancer in northern Italy. Int J Cancer 1988; 41:492-498.
30. Wynder EL, Kajitani T, Ishikawa S, Dodo H, Takano A. Environmental factors of cancer of the colon and rectum. II. Japanese epidemiological data. Cancer 1969; 23:1210-1220.
31. Wasan HS, Goodlad RA. Fibre-supplemented foods may damage your health. Lancet 1996; 348:319-320.
32. Prentice RL, Sheppard L. Dietary fat and cancer: consistency of the epidemiologic data, and disease prevention that may follow from a practical reduction in fat consumption. Cancer Causes Control 1990; 1:81-97.
33. Thun MJ, Calle EE, Namboodiri MM, et al. Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst 1992; 84:1491-1500.
34. Goldbohm RA, van den Brandt PA, vant’Veer P, Dorant E, Sturmans F, Hermus RJ. Prospective study on alcohol-consumption and the risk of cancer of the colon and rectum in the Netherlands. Cancer Causes Control 1994;5:95-104.
35. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Speizer FE. Relation of meat, fat and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med 1990; 323:1664-1672.
36. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121:241-246.
37. Key TJA, Thorogood M, Appleby PN, Burr ML. Dietary habits and mortality in 11000 vegetarians and health conscious people: results of a 17 year follow-up. BMJ 1996; 313:775-778.
38. International Agency for Research on Cancer. Coffee, tea, mate, methylxanthines and methylglyoxal. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 51. Lyon: International Agency for Research on Cancer, 1991.
39. International Agency for Research on Cancer. Alcohol drinking. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 44. Lyon: International Agency for Research on Cancer, 1988.
40. Longnecker MP, Orza MJ, Adams ME, Vioque J, Chalmers TC. A meta-analysis of alcoholic beverage consumption in relation to risk of colorectal cancer. Cancer Causes Control 1990; 1:59-68.
41. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333:609-614.
42. Jensen OM. The role of diet in colorectal cancer. International Congress Service 1985; 685:137-147.
43. Kune S, Kune GA, Watson LF. Case-control study of dietary etiological factors: the Melbourne colorectal cancer study. Nutr Cancer 1987; 9:21-12.
44. Giovannucci E, Stampfer MJ, Colditz GA, Rimm EB, Trichopoulos D, Rosner BA, Speizer FE, Willett WC. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst 1993; 85:875-884.
45. White E, Jacobs EJ, Daling JR. Physical activity in relation to colon cancer in middle-aged men and women. Am J Epidemiol 1996; 144:42-50.
46. Albanes D, Taylor PR. International differences in body height and weight and their relationship to cancer incidence. Nutr Cancer 1990; 14:69-77.
47. Fraumeni JF, Lloyd JW, Smith EM, et al. Cancer mortality among nuns: role of marital status in etiology of neoplastic disease in women. J Natl Cancer Inst 1969; 42:455-468.
48. McMichael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones and colon cancer: a review and hypothesis. J Natl Cancer Inst 1980; 65:1201-1207.
49. Cuzick J. Medicinal drugs and hormonal activity as chemopreventive agents. In: B.W. Stewart BW, McGregor D, Kleihues P, eds. Principles of Chemoprevention [IARC Scientific Publications No. 139]. Lyon: International Agency for Research on Cancer, 1996:99-114.
50. Calkins BM, Mandeloff Al. Epidemiology of inflammatory bowel disease. Epidemiol Rev 1986; 8:60-91.
51. Glickman RM. Inflammatory bowel disease. In: Braunwald E, Isselbacher K, Petersdorf RG, et al, eds. Harrison’s Principles of Internal Medicine. New York: McGraw-Hill, 1987; 1277-1290.
52. Weeden DD, Shorter RG, Ilstrup DM, Huizenga KA, Taylor WF. Crohn’s disease and cancer. N Engl J Med 1973; 289:1099-1103.
53. Greenstein AJ, Sachar DB, Smith H, Janowitz HD, Aufses AH Jr. Patterns of neoplasia in Crohn’s disease and ulcerative colitis. Cancer 1980; 46:403-407.
54. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancok B, Kwong E, Trzaskos JM, Evans JF, Taketo MM. Suppression of intestinal polyposis in ape716 knockout mice by inhibition of cyclo-oxygenase 2 (Cox-2). Cell 1966; 87:803-809.
55. Trujillo MA, Garewal HS, Sampliner RE. Nonsteroidal anti-inflammatory agents in chemoprevention of colorectal cancer at what cost? Dig Dis Sci 1994; 39:2260-2266.
56. Greenberg ER, Baron JA. Aspirin and other nonsteroid anti-inflammatory drugs as cancer-preventive agents. In: Stewart BW, McGregor D, Kleihues P, eds. Principles of Chemoprevention [IARC Scientific Publications No. 139]. Lyon: International Agency for Research on Cancer 1996:91-98.
57. Guillem JG, Neugut Al, Forde KA, Waye JD, Treat MR. Colonic neoplasms in asymptomatic first-degree relatives of colon cancer patients. Am J Gastroenterol 1988; 83:271-273.
58. Burt RW. Familial risk and colon cancer. Int J Cancer 1996; 69:44-46.
59. Morson BC, Bussey HJR, Day DW, Hill MJ. Adenomas of large bowel. Cancer Surv 1983; 2:451-477.
60. Morson BC. Factors influencing the prognosis of early cancer of the rectum. Proc R Soc Med 1966; 59:607-608.
61. Muto T, Bussey HJR, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975; 36:2251-2270.
62. Stryker SJ, Wolff BG, Culp CE, Libbe SD, Ilstrup DM, MacCarty RL. Natural history of untreated colonic polyps. Gastroenterology 1987; 93:1009-1013.
63. Eide TJ. Risk of colorectal cancer in adenoma-bearing individuals within a defined population. Int J Cancer 1986; 38:173-176.
64. Lotfi AM, Spencer RJ, Ilstrup DM, Melton LJ III. Colorectal polyps and risk of subsquent carcinoma. Mayo Clin Proc 1986; 61:337-343.
65. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992; 326:658-662.
66. Rex DK, Lehman GA, Hawes RH, Ulbright TM, Smith JJ. Screening colonoscopy in asymptomatic average-risk persons with negative fecal occult blood tests. Gastroenterology 1991; 100:64-67.
67. Williams AR, Balasooriya BAW, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut 1982; 123:835-842.
68. Clark JC, Collan Y, Eide TJ, Esteve J, Ewen S, Gibbs NM, Jensen OM, Koskela E, MacLennan R, Simpson JG, Stalsberg H, Zaridze DG. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer 1985; 36:179-186.
69. Johannsen LGK, Momsen O, Jacobsen NO. Polyps of the large intestine in Aarhus, Denmark. Scand J Gastroenterol 1989;24:799-806.
70. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL. Genetic alterations during colorectal tumour development. N Engl J Med 1988; 319:525-532.
71. Jessup JM, Gallick GE. The biology of colorectal carcinoma. Curr Probl Cancer 1992; 16:265-327.
72. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW. APC mutations occur early during colorectal tumori-genesis. Nature 1992; 359:235-237.
73. Froggatt NJ, Joyce JA, Davies, R, Gareth D, Evans R, Ponder BA, Barton DE, Maher ER. A frequent hMSH2 mutation in hereditary non-polyposis colon cancer syndrome. Lancet 1995; 345:727.
74. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, Van der EB JA, Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327:293-297.
75. Breivik J, Meling GI, Spurkland A, Rognum TO, Gaudernack G. K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br J Cancer 1994; 69:367-371.
76. Houlston RS, Collins A, Slack J, Morton NE. Ann Hum Genet 1992; 56:99-103.
77. Lynch HT, Smyrk TC, Watson P, Watson P, Lanspa SJ, Lynch JF, Lynch PM, Cavalieri RJ, Boland CR. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 1993; 104:1535-1549.
78. Deleon MP, Sassatelli R, Benatti P, Roncucci L. Identification of hereditary nonpolyposis colorectal cancer in the general-population-the 6-year experience of a population-based registry. Cancer 1993; 71:3493-3501.
79. Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystromlahti M, Pylkkanen L, Heimdal K, Andersen TI, Moller P, Rognum TO. Genomic instability in colorectal cancer-relationship to clinicopathological variables and family history. Cancer Res 1993; 53:5849-5852.
80. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jar-vinen H, Powell SM, Jen J, Hamilton SR, Petersen GM, Kinzler KW, Vogelstein B, de la Chapelle A. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260:812-816.
81. Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64:430-433.
82. Lang NP, Butler MA, Massengil J, et al. Rapid metabolic phenotypes for acetyl-transferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk of colorectal cancer of polyps. Cancer Epidemiol Biomarkers Prev 1994; 3:675-682.
83. Zhong S, Wyllie AH, Barnes D, et al. Relationship between GSTMI genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 1994; 14:1821-1824.
84. Simon JB. Occult blood screening for colorectal carcinoma: a critical review. Gastroenterology 1985; 88:820-837.
85. Lauridsen LH, Bohn L. Testing of feces for occult blood: a review. Dan Med Bull 1976; 23:230-235.
86. Irons GV, Kirsner JB. Routine chemical tests of the stool for occult blood: an evaluation. Am J Med Sei 1965; 249:247-260.
87. Greegor DH. Diagnosis of large-bowel cancer in the asymptomatic patient. JAMA 1967; 201:943-945.
88. Morris DW, Hansell JR, Ostrow JD, Lee CS. Reliability of chemical tests for fecal occult blood in hospitalized patients. Am J Dig Dis 1976; 21:845-852.
89. Wells HJ, Pagano JF. “Hemoccult” test-reversal of false-negative results due to storage (abstr). Gastroenterology 1977; 72:1148.
90. Winawer SJ, Andrews M, Fleichinger B, Sherlock P, Schottenfeld D, Miller DG. Progress report on controlled trial of fecal occult blood testing for the detection of colorectal neoplasia. Cancer 1980; 45:2959-2964.
91. Kewenter J, Björk S, Haglind E, Smith L, Svanvik J, Ahrén C. Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27 700 subjects. Cancer 1988; 62:645-651.
92. Atkin WS, Cuzick J, Northover JMA, Whynes DK. Prevention of colorectal cancer by once-only sigmoidoscopy. Lancet 1993; 341:736-740.
93. Eddy DM. Screening for colorectal cancer. Ann Intern Med 1990; 113:373-384.
94. Ott DJ. Role of the barium enema in colorectal carcinoma. Radiol Clin North Am 1993; 31:1293-1313.
95. Ott DJ, Scharling ES, Chen YM, et al. Barium enema examination: sensitivity in detecting colonic polyps and carcinomas. South Med J 1989; 82:197-200.
96. Stevenson GW. Radiology and endoscopy in the pretreatment diagnostic management of colorectal cancer. Cancer 1993; 71:4198-4206.
97. Lieberman D. Cost-effectiveness of colon cancer screening. Am J Gastroenterol 1991; 86:1789-1794.
98. Lieberman DA, Smith FW. Screening for colon malignancy with colonoscopy. Am J Gastroenterol 1991; 86:946-951.
99. Williams C. Electronic 3-dimensional imaging of intestinal endoscopy. Lancet 1993;341:724-725.
100. Miyoshi Y, Ando H, Nagase H, Nishisho I, Horii A, Miki Y, Mori T, Utsunomiya J, Baba S, Petersen G, Hamilton SR, Kinzler KW, Vogelstein B, Nakamura Y. Germ-line mutations of the Ape gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sei USA 1992; 89:4452-4456.
101. Cottrell S, Bicknell D, Kaklamanis L, Bodmer WF. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet 1992; 340:626-630.
102. Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelstein B. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992;256:102-105.
103. Tobi M, Luo F-C, Ronai Z. Detection of K-ras mutation in colonic effluent samples from patients without evidence of colorectal carcinoma. J Natl Cancer Inst 1994;86:1007-1010.
104. Smith-Ravin J, England J, England J, Talbot IC, Bodmer W. Detection of c-Ki-ras mutations in fecal samples from sporadic colorectal cancer patients. Gut 1995; 36:81-86.
105. Villa E, Dugani A, Rebecchi AM, Vignoli A, Grottola A, Buttafoco P, Losi L, Perini M, Trande P, Merighi A, Lerose R, Manenti F. Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. Gastroenterology 1996; 110:1346-1353.
106. Friedman GD, Collen MF, Fireman BH. Multiphasic health checkup evaluation: a 16-year follow-up. J Chron Dis 1986; 39:453-463.
107. Herrinton L, Selby JV, Friedman GD, Quesenberry CP, Weiss NS. A case-control study of digital-rectal screening in relation to mortality from cancer of the distal rectum. Am J Epidemiol 1995; 141:11.
108. Ahlquist DA, Wieand S, Moertel CG, McGill DB, Loprinzi CL, O’Connell MJ, Mailliard JA, Gerstner JB, Pandya K, Ellefson RD. Accuracy of fecal occult blood screening for colorectal neoplasia. JAMA 1993; 269:1262-1267.
109. St. John DJB, Young GP, Alexeyeff MA, Deacon MC, Cuthbertson A M, Macrae FA, Penfold JCB. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology 1993; 104:1661-1668.
110. Castiglione G, Zappa M, Grazzini G, Mazzotta A, Biagini M, Salvadori P, Ciatto S. Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer. Br J Cancer 1996; 74:141-144.
111. Petrelli N, Michalek AM, Freedman A, Baroni M, Mink I, Rodriguez-Bigas M. Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program. Surg Oncol 1994; 3:27-36.
112. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, En-derer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993; 328:1365-1371.
113. Kewenter J, Asztely M, Engaras B, et al. A randomised trial of faecal occult blood testing for early detection of colorectal cancer. In: Miller AB, Chamberlain J, Day NE, et al, eds. Cancer Screening. Results of Screening and Rescreening of 51325 Subjects. Cambridge: Cambridge University Press 1991:116-125.
114. Rozen P, Ron E, Fireman Z, Figer A, Legum C, Ron E. The relative value of fecal occult blood tests and flexible sigmoidoscopy in screening for large bowel neoplasia. Cancer 1987; 60:2553-2583.
115. Hardcastle JD, Chamberlain JO, Robinson MHE, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348:1472-1477.
116. Kronberg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348:1467-1471.
117. Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 1993; 85:1311-1318.
118. Selby JV, Friedman GD, Quesenberry CP, Weiss NS. Effect of fecal occult blood testing on mortality from colorectal cancer. A case-control study. Ann Intern Med 1993; 118:1-6.
119. Wahrendorf J, Robra BP, Wiebelt H, Oberhausen R, Weiland M, Dhom G. Effectiveness of colorectal cancer screening: results from a population-based case-control evaluation in Saarland, Germany. Eur J Cancer Prev 1993; 2:221-227.
120. Saito H, Soma Y, Koeda J, Wada Toyohito, Kawaguchi H, Sobue T, Aisawa T, Yoshida Y. Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study. Int J Cancer 1995; 61:465-469.
121. Lazovich DA, Weiss NS, Stevens NG, White E, McKnight B, Wagner EH. A case-control study to evaluate efficacy of screening faecal occult blood. J Med Screening 1995, 2:84-89.
122. Atkin WS, Hart A, Edwards R, Mclntyre P, Aubrey R, Wardle J, Sutton S, Cuzick J, Northover JMA. Uptake, yield of neoplasia and adverse effects of flexible sigmoidoscopy screening. Gut 1998; 42:560-565.
123. Olynyk JK, Aquilia S, Fletcher DR, Dickinson JA. Flexible sigmoidoscopy screening for colorectal cancer in average-risk subjects: a community-based pilot project. MJA 1996; 165:74-76.
124. Hoff G, Sauar J, Vatn MH, Larsen S, Langmark F, Moen IE, Foerser A, Thiis-Evensen E. Polypectomy of adenomas in the prevention of colorectal cancer: 10 years’ follow-up of the Telemark Polyp Study I. Scand J Gastroenterol 1996; 31:1006-1010.
125. Gilbertson VA, Nelms JM. The prevention of invasive cancer of the rectum. Cancer 1978; 41:1137-1139.
126. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992; 326:653-657
127. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992; 84:1572-1575.
128. Muller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer: a case-control study among veterans. Arch Intern Med 1995; 155:1741-1748.
129. Winawer SJ, Zauber AG, Ho MN, O’Brien MJ, Gottleib LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF, Ackroyd F, Shike M, Kurtz RC, Hornsby-Lewis L, Gerdes H, Stewart ET, and the National Polyp Study Workgroup. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993; 329:1977-1981.
130. Meagher AP, Stuart M. Does colonoscopic polypectomy reduce the incidence of colorectal carcinoma? Aust N Z J Surg 1994;64:400-404.
131. Choi PM, Nugent FW, Schoetz DJ, Silverman ML, Haggitt RC. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993; 105:418-424.
132. Macrae FA, Tan KG, Williams CB. Towards safer colonoscopy: a report on the complications of 5000 diagnostic or therapeutic colonoscopies. Br Med Assoc 1983; 24:376-383.
133. Waye JD, Lewis BS, Yessayan S. Colonoscopy: a prospective report of complications. J Clin Gastroenterol 1992; 15:347-351.
134. Winnan G, Berci G, Panish J, Talbot TM, Overholt BF, McCallum RW. Superiority of the flexible to the rigid sigmoidoscope in routine proctosigmoidoscopy. N Engl J Med 1980; 302:1011-1012.
135. Portes C, Majarakis JD. Proctosigmoidoscopy: incidence of polyps in 50, 000 examinations. JAMA 1957; 163:411-413.
136. Wagner JL, Tunis S, Brown M, Ching A, Almeida R. Cost-effectiveness of colorectal cancer screening in average-risk adults. In: Young G, Levin B, eds. Prevention and Early Detection of Colorectal Cancer. London: Saunders, 1996.
137. Walker A, Whynes DK, Chamberlain, JO, Hardcastle JD. The cost of screening for colorectal cancer. Epidemiol Community Health 1991; 45:220-224.
138. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112:594-642.
139. Griffith CDM, Turner DJ, Saunders JH. False negative results of Hemoccult test in colorectal screening. BMJ 1981; 283:472-473.
140. Macrae FA, St. John DJ. Relationship between patterns of bleeding and Haemoc-cult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology 1982; 82:891.
141. Doran J, Hardcastle JD. Bleeding patterns in colorectal cancer: the effect of aspirin and the implications for faecal occult blood testing. Br J Surg 1982; 69:711-713.
142. Farrands PA, Hardcastle JD. Accuracy of occult blood tests over a six-day period. Clin Oncol 1983; 9:217-225.
143. McDonald C, Goulston K. Colorectal test for occult blood. Med J Aust 1984; 140: 183.
144. Ahlquist DA, McGill DB, Schwartz S, Taylor WF, Owen RA. Fecal blood levels in health and disease. A study using HemoQuant. N Engl J Med 1985; 312:1422-1428.
145. Crowley ML, Freeman LD, Mottet MD, Strong RM, Sweeney BF, Brower RA, Sharma SP, Anderson DS. Sensitivity of guaiac-impregnated cards for the detection of colorectal neoplasia. J Clin Gastroenterol 1983; 5:127-130.
146. Songster CL, Barrows GH, Jarrett DD. Immunochemical detection of fecal occult blood-the fecal smear punch-disc test: a new non-invasive screening test for colorectal cancer. Cancer 1980; 45:1099-1102.
147. Kapparis A, Frommer D. Immunological detection of occult blood in bowel cancer patients. Br J Cancer 1985; 52:857-861.
148. Greegor DH. Detection of silent colon cancer in routine examination. CA 1969; 19:330-337.
149. Hastings JB. Mass screening for colorectal cancer. Am J Surg 1974; 127:228-233.
150. Miller SF, Knight AR. The early detection of colorectal cancer. Cancer 1977; 40:945-949.
151. Goodman MJ. Mass screening for colorectal cancer-a negative report. JAMA 1977; 237:2380.
152. Helfrich GB, Petrucci P, Webb H. Mass screening for colorectal cancer. JAMA 1977; 238:1502-1503.
153. Fruhmorgen P, Demling L. Early detection of colorectal carcinoma with a modified guaiac test. A screening examination in 6000 humans. Acta Gastroenterol Belg 1978; 41:682-687.
154. Heeb MA, Ahlvin RC. Screening for colorectal carcinoma in a rural area. Surgery 1978; 83:540-541.
155. Elwood TW, Erickson A, Lieberman S. Comparative educational approaches to screening for colorectal cancer. Am J Public Health 1978; 68:135-138.
156. Bralow SP, Kopel J. Hemoccult screening for colorectal cancer. An impact study on Sarasota, Florida. J Florida Med Assoc 1979; 66:915-919.
157. Winchester DP, Shull JH, Scanion EF, Murrel JV, Smeltzer C, Vrba P, Iden M, Streelman DH, Magpayo R, Dow JW, Sylvester J. A mass screening program for colorectal cancer using chemical testing for occult blood in the stool. Cancer 1980; 45:2955-2958.
158. Kurnick JE, Walley LB, Jacob HH, et al. Colorectal cancer detection in a community hospital screening program. JAMA 1980; 243:2056-2057.
159. Gnauck R, Thomas L. Haemoscreen in Vergleich mit Haemoccult als Suchtest auf kolorektalen. Krebs Dtsch Med Wschr 1980; 105:1642-1646.
160. Schwartz FW, Holstein H, Brecht JG. Preliminary report of fecal occult blood testing in Germany. In: Winawer SJ, Schottenfeld D, Sherlock P, eds. Colorectal Cancer: Prevention, Epidemiology, and Screening. New York: Raven, 1980:267-270.
161. Larkin KK. Mass screening in colorectal cancer. Aust NZ J Surg 1980; 50:467-469.
162. Chambers KJ, Morgan BP. Mass screening in colorectal cancer. Aust NZ J Surg 1980; 50:467-469.
163. Stuart M, Killingback MJ, Sakker S, et al. Hemoccult II test. Routine screening procedure for colorectal neoplasm? Med J Aust 1981; i:629-631.
164. Farrands PA, Griffiths RL, Britton DC. The Frome experiment-value of screening for colorectal cancer. Lancet 1981; i: 1231-1232.
165. Million R, Howarth J, Turnberg E, Turnberg LA. Faecal occult blood testing for colorectal cancer in general practice. Practitioner 1982; 226:659-663.
166. Sontag SJ, Durczak C, Aranha GV, Chejfec G, Frederick W, Greenlee HB. Fecal occult blood screening for colorectal cancer in a Veterans Administration hospital. Am J Surg 1983; 145:89-93.
167. Hardcastle JD, Farrands PA, Balfour TW, Chamberlain J, Amar SS, Sheldon MG. Controlled trial of faecal occult blood testing in the detection of colorectal cancer. Lancet 1983; ii:1-4.
168. Siba S. Experience with Haemoccult screening in Hungary. A multicenter trial. Hepatogastroenterol 1983; 30:27-29.
169. Habba SF, Doyle JS. Colorectal cancer screening of asymptomatic patients in Ireland. Ir J Med Sci 1983; 152:121-124.
170. Armitage N, Hardcastle JD, Amar SS, Balfour TW, Haynes J, James PD. A comparison of an immunological faecal occult blood test Fecatwin sensitive/FECA EIA with Haemoccult in population screening for colorectal cancer. Br J Cancer 1985; 51:799-804.
171. Thomas WM, Pye G, Hardcastle JD, Mangham CM. Faecal occult blood screening for colorectal neoplasia: a randomized trial of three days or six days of tests. Br J Surg 1990; 77:277-279.
172. McGarrity TJ, Long PA, Peiffer LP. Results of a repeat television-advertised mass screening program for colorectal cancer using fecal occult blood tests. Am J Gastroenterol 1990; 85:266-270.
173. Caffarey SM, Broughton CI, Marks CG. Faecal occult blood screening for colorectal neoplasia in a targeted high-risk population. Br J Surg 1993; 80:1399-1400.
174. Robinson MHE, Marks CG, Farrands PA, Thomas WM, Hardcastle JD. Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests. Br J Surg 1994; 81:448-451.
175. Castiglione G, Biagini M, Barchielli A, Grazzini G, Mazzotta A, Salvadori P, Scillone L, Ciatto S. Effect of rehydration on guaiac-based faecal occult blood testing in colorectal cancer screening. Br J Cancer 1993; 67:1142-1144.
176. McCallum RW, Meyer CT, Marignani P, et al. Flexible sigmoidoscopy: diagnostic yield in 1015 patients. Am J Gastroenterol 1984; 79:433-437.
177. Rosevelt J, Frankl H. Colorectal cancer screening by nurse practitioner using 60-cm flexible fiberoptic sigmoidoscope. Dig Dis Sci 1984; 29:161-163.
178. Shida H, Yamamoto T. Fiberoptic sigmoidoscopy as the first screening procedure for colorectal neoplasms in an asymptomatic population. Dis Colon Rectum 1989; 32:404-408.
179. Reilly JM, Ballantyne GH, Fleming FX, Zucker KA, Modlin IM. Evaluation of the occult blood test in screening for colorectal neoplasms. A prospective study using flexible endoscopy. American Surgeon 1990; 56:119-123.